Wolfgang Gleiber

666 total citations
20 papers, 220 citations indexed

About

Wolfgang Gleiber is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Wolfgang Gleiber has authored 20 papers receiving a total of 220 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Wolfgang Gleiber's work include Lung Cancer Treatments and Mutations (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Cystic Fibrosis Research Advances (6 papers). Wolfgang Gleiber is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Cystic Fibrosis Research Advances (6 papers). Wolfgang Gleiber collaborates with scholars based in Germany, United Kingdom and United States. Wolfgang Gleiber's co-authors include Judith Atz, R. Kaiser, Siegfried Haas, Thomas Wagner, Arnd Nusch, Joerg Bojunga, Mireen Friedrich‐Rust, Martina Jänicke, Norbert Marschner and Volker Hagen and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

Wolfgang Gleiber

20 papers receiving 219 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wolfgang Gleiber Germany	8	134	92	43	38	18	20	220
Araceli Alemán Spain	4	49 0.4×	112 1.2×	39 0.9×	27 0.7×	21 1.2×	4	218
Perrine Vuagnat France	10	96 0.7×	274 3.0×	81 1.9×	24 0.6×	31 1.7×	34	388
Julie M. Shabto United States	9	98 0.7×	187 2.0×	56 1.3×	23 0.6×	17 0.9×	35	292
Makiko Yomota Japan	11	206 1.5×	172 1.9×	21 0.5×	23 0.6×	19 1.1×	39	302
Elizabeth Hodgkinson United Kingdom	6	114 0.9×	207 2.3×	39 0.9×	22 0.6×	36 2.0×	10	308
Elena Orlandi Italy	11	108 0.8×	136 1.5×	29 0.7×	13 0.3×	34 1.9×	29	249
Emre Yekedüz Türkiye	9	107 0.8×	163 1.8×	31 0.7×	13 0.3×	38 2.1×	63	296
Laureen Ribassin-Majed France	8	90 0.7×	145 1.6×	157 3.7×	97 2.6×	36 2.0×	15	452
Chunchun Shao China	8	25 0.2×	90 1.0×	34 0.8×	48 1.3×	25 1.4×	19	225
Turab Mohammed United States	8	75 0.6×	102 1.1×	42 1.0×	20 0.5×	28 1.6×	28	235

Countries citing papers authored by Wolfgang Gleiber

Since Specialization

Citations

This map shows the geographic impact of Wolfgang Gleiber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wolfgang Gleiber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wolfgang Gleiber more than expected).

Fields of papers citing papers by Wolfgang Gleiber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wolfgang Gleiber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wolfgang Gleiber. The network helps show where Wolfgang Gleiber may publish in the future.

Co-authorship network of co-authors of Wolfgang Gleiber

This figure shows the co-authorship network connecting the top 25 collaborators of Wolfgang Gleiber. A scholar is included among the top collaborators of Wolfgang Gleiber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wolfgang Gleiber. Wolfgang Gleiber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sutharsan, Sivagurunathan, Rainald Fischer, Wolfgang Gleiber, et al.. (2024). Randomised, phase 1/2a trial of ION-827359, an antisense oligonucleotide inhibitor of ENaC. ERJ Open Research. 10(4). 986–2023. 1 indexed citations

Sutharsan, Sivagurunathan, Rainald Fischer, Wolfgang Gleiber, et al.. (2022). Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION-827359, an Antisense Oligonucleotide Inhibitor of ENaC, in Healthy Volunteers and Patients with Cystic Fibrosis: A Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2a Study. SSRN Electronic Journal. 1 indexed citations

Grohé, Christian, Werner J. Blau, Wolfgang Gleiber, et al.. (2022). Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study. Clinical Oncology. 34(7). 459–468. 13 indexed citations

Grohé, Christian, Wolfgang Gleiber, Siegfried Haas, et al.. (2020). 1372P Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) after failure of previous immune checkpoint inhibitor therapy (ICIs): Updated results from the ongoing non-interventional study (NIS) VARGADO (NCT02392455). Annals of Oncology. 31. S875–S876. 1 indexed citations

Grohé, Christian, Wolfgang Blau, Wolfgang Gleiber, et al.. (2020). Nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated efficacy and safety results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455).. Journal of Clinical Oncology. 38(15_suppl). 9604–9604. 5 indexed citations

Greulich, Timm, Sebastian Fähndrich, Christian F. Clarenbach, et al.. (2020). Alpha-1-Antitrypsin-Mangel (AATM) – Ein Expertenstatement. Pneumologie. 74(7). 436–442. 1 indexed citations

Stratmann, Jan, Shabnam Shaid, Wolfgang Gleiber, et al.. (2020). Colonization with multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancer. PLoS ONE. 15(11). e0242544–e0242544. 12 indexed citations

Marschner, Norbert, Stefan Zacharias, Florian Lordick, et al.. (2020). Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer. JAMA Network Open. 3(3). e200643–e200643. 55 indexed citations

Gleiber, Wolfgang, et al.. (2019). Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First results of the ongoing non-interventional study (NIS) VARGADO. Annals of Oncology. 30. ii48–ii48. 1 indexed citations

10.

Koningsbruggen‐Rietschel, Silke van, Katja Conrath, Rainald Fischer, et al.. (2019). GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN). Journal of Cystic Fibrosis. 19(2). 292–298. 10 indexed citations

11.

Griesinger, Frank, Wilfried Eberhardt, Harald-Robert Bruch, et al.. (2019). Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315). Annals of Oncology. 30. v616–v616. 1 indexed citations

12.

Grohé, Christian, Wolfgang Gleiber, Siegfried Haas, et al.. (2019). Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO. Annals of Oncology. 30. v618–v618. 1 indexed citations

13.

Grohé, Christian, Wolfgang Blau, Wolfgang Gleiber, et al.. (2019). Nintedanib plus docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Preliminary efficacy and safety results of the non-interventional study VARGADO.. Journal of Clinical Oncology. 37(15_suppl). 9074–9074. 3 indexed citations

14.

Grohé, Christian, Wolfgang Gleiber, Siegfried Haas, et al.. (2019). Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitor Therapy: Insights from VARGADO, A Prospective Study in Patients with Lung Adenocarcinoma. Future Oncology. 15(23). 2699–2706. 21 indexed citations

15.

Kuon, Jonas, Farastuk Bozorgmehr, Martin Schneider, et al.. (2018). Durvalumab in frail and elder patients with stage four NSCLC: The DURATION trial. Annals of Oncology. 29. viii546–viii547. 1 indexed citations

16.

Fuchs, Susanne, Nicolaus Schwerk, Klaus Pittschieler, et al.. (2016). Lung clearance index for monitoring early lung disease in alpha-1-antitrypsin deficiency. Respiratory Medicine. 116. 93–99. 14 indexed citations

17.

Mainz, Jochen G., Julia Hentschel, Ulrike Schumacher, et al.. (2015). 146 Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis – results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis. 14. S95–S95. 7 indexed citations

18.

Fuchs, Susanne, Nicolaus Schwerk, Klaus Pittschieler, et al.. (2014). Lung Clearance Index zur Früherkennung der Lungenerkrankung bei Patienten mit Alpha-1-Antitrypsinmangel und verschiedenen Genotypen. Pneumologie. 68(S 01). 1 indexed citations

19.

Friedrich‐Rust, Mireen, Christina Smaczny, Olaf Eickmeier, et al.. (2013). Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis. Journal of Cystic Fibrosis. 12(5). 431–439. 57 indexed citations

20.

Hirche, T. O., Judy Bradley, K. De Boeck, et al.. (2010). Travelling with cystic fibrosis: Recommendations for patients and care team members. Journal of Cystic Fibrosis. 9(6). 385–399. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact